Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bionano GenomicsMEX:BNGO +5.05%62 Days Payable is 115.85 as of Jun. 2026, which is 10% below its 10-year median of 129.36. GuruFocus rates MEX:BNGO with a GF Score™ of 62/100 and a GF Value™ of MXN16.20 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 793 Medical Devices & Instruments companies, Bionano Genomics ranks better than 73.64% on this metric.
The historical rank and industry rank for Bionano Genomics's Days Payable or its related term are showing as below:
MEX:BNGO'
s Days Payable Range Over the Past 10 Years
Min: 76.57 Med: 129.36 Max: 194.57
Current: 126.49
During the past 10 years, Bionano Genomics's highest Days Payable was 194.57. The lowest was 76.57. And the median was 129.36.
MEX:BNGO's Days Payable is ranked better than 73.64% of 793
companies
in the Medical Devices & Instruments industry
Industry Median: 68.47
vs MEX:BNGO: 126.49
Bionano Genomics's Days Payable
declined
from Jun. 2025 (187.40) to Jun. 2026 (115.85).
It may suggest that Bionano Genomicsaccelerated paying its suppliers.
The historical data trend for Bionano Genomics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BNGO vs RGNT, UEEC, FEMY: Days Payable Comparison
For the Medical Instruments & Supplies subindustry, Bionano Genomics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionano Genomics Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's Days Payable distribution charts can be found below:
* The bar in red indicates where Bionano Genomics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Bionano Genomics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionano Genomics (MEX:BNGO) has a Days Payable of 115.85 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bionano Genomics and its competitors. This is 10% below median its historical median of 129.36. Over the past decade, Bionano Genomics' Days Payable has ranged from 76.57 to 194.57. According to the industry distribution chart, Bionano Genomics ranks #209 out of 793 companies in the Medical Devices & Instruments industry, placing it in the top 26.4%.
Is Bionano Genomics' Days Payable too high?
Bionano Genomics' current Days Payable of 115.85 is 10% below median its 10-year median of 129.36. Over the past 10 years, this metric has ranged from a low of 76.57 to a high of 194.57. The Medical Devices & Instruments industry median Days Payable is 68.47. Bionano Genomics' value of 115.85 is 69.2% above this industry median. Based on the distribution chart, Bionano Genomics ranks #209 out of 793 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bionano Genomics has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bionano Genomics' Days Payable compare to RGNT and UEEC?
According to the Medical Devices & Instruments industry distribution chart, Bionano Genomics ranks #209 out of 793 companies for Days Payable. This puts Bionano Genomics in the upper half of its industry. The industry median Days Payable is 68.47. Bionano Genomics' value of 115.85 is 69.2% above this benchmark. Historically, Bionano Genomics' own Days Payable has ranged from 76.57 to 194.57 over the past decade. While the company's 10-year median is 129.36 vs. the industry median of 68.47, Bionano Genomics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.47, based on 793 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bionano Genomics's current Days Payable of 115.85 is 69.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bionano Genomics and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionano Genomics's current Days Payable is 115.85, which is 10% below median its own 10-year median of 129.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionano Genomics stock overvalued right now?
Based on GuruFocus' analysis, Bionano Genomics (MEX:BNGO) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN16.20, compared to a current price of MXN21.00 — trading 29.6% above its estimated fair value. The current Days Payable is 115.85, which is 10% below median its 10-year median of 129.36 and 69.2% above the Medical Devices & Instruments industry median of 68.47. Bionano Genomics' overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Bionano Genomics (MEX:BNGO), the current Days Payable is 115.85 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bionano Genomics (MEX:BNGO) Overvalued in 2026?
Based on GuruFocus' analysis, Bionano Genomics stock appears to be overvalued.
The current stock price of MXN21.00 is trading 29.6% above its estimated GF Value™ of MXN16.20.
GuruFocus considers Bionano Genomics to be Modestly Overvalued.
Key valuation signals for MEX:BNGO:
Days Payable: 115.85 (10% below median its 10-year median of 129.36)
GF Value™: MXN16.20 vs. price of MXN21.00 (29.6% above fair value)
Industry Position: 69.2% above the Medical Devices & Instruments median (#209 of 793)
No single metric tells the full story. See the MEX:BNGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
62GF Score
Get the complete analysis for MEX:BNGO
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BNGO has been successfully added to your 
